CJC-1295 with DAC

ACTIVE HALF-LIFE 6-8 hours
CLASSIFICATION Peptide Hormone
DOSAGE 300 mcg/day
ACNE No
WATER RETENTION No
HBR No
HEPATOTOXICITY No
AROMATIZATION No
MANUFACTURER Hilma Biocare
WAREHOUSE EU Warehouse 3
SUBSTANCE GHRH Peptide ,

CJC-1295 DAC was first introduced in 2005 by the Canadian biotechnology firm ConjuChem. Unlike GHRP group peptides, CJC-1295 DAC provides a steady release of growth hormone in small amounts, avoiding sharp spikes in blood GH levels and mimicking the effects of growth hormone. A single injection can lead to a 2-10 fold increase in hormone concentration over a period of six days. Athletes often use it for various performance enhancement purposes.

Athletes utilizing CJC-1295 DAC can enhance muscle growth and overall performance while also reducing unwanted fat. Additionally, it promotes collagen production, aiding in the strengthening of tendons and ligaments, and contributes to general health.

As a peptide, CJC-1295 DAC is less likely to cause adverse effects commonly associated with anabolic steroids. The most frequently reported side effects include water retention and feelings of weakness.

CJC-1295 DAC yields impressive results and can be safely combined with other peptides, anabolic steroids (AAS), and human growth hormone (HGH).